US0311621009
US0311621009
Amgen Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 224.29B EUR | 195.76B EUR | 189.89B EUR | 176.35B EUR |
Enterprise Value | 263.59B EUR | 239.08B EUR | 235.18B EUR | 221.83B EUR |
Valuation Multiples | ||||
Trailing P/E | 25.77x | 22.39x | 24.35x | 29.49x |
Forward P/E | 16.94x | -- | -- | -- |
Price to Sales | 5.89x | 5.14x | 5.1x | 6.17x |
Price to Book | 19.19x | 16.75x | 20.66x | 20.37x |
EV/Revenue | 6.92x | 6.28x | 6.32x | 7.76x |
EV/EBITDA | 15.27x | 13.57x | 14.11x | 17.31x |
Price to FCF (P/FCF) | 25.94x | 19.24x | 22.09x | 24.77x |
EV/FCF | 30.49x | 23.5x | 27.36x | 31.16x |
FCF Yield | 3.85% | 5.2% | 4.53% | 4.04% |